Bremelanotide
Bremelanotide is a prescription melanocortin agonist studied for a defined form of low sexual desire associated with distress. It is also known as PT-141.
Prescription medicines
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Sexual function, reproductive hormones, and obstetric care.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for reproductive health: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| FDA-approved medicine (6)Approved for the specific uses on its label, which may not be this goal. | |||
| Bremelanotide | RECONNECT (2019) · Human randomized trial Desire scores improved and distress scores decreased more with treatment. Nausea, flushing, and headache were more frequent. Limitation: The endpoints were validated symptom scales. These results do not establish treatment for every cause of low desire, male erectile dysfunction, or general sexual performance. Studied: 1,267 premenopausal women randomized across two studies of hypoactive sexual desire disorder. | FDA-approved | FDA label |
| Degarelix | PRONOUNCE (2021) · Human randomized trial Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53). Limitation: Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence. Studied: 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900. | FDA-approved | FDA label |
| HCG | HCG and clomiphene in male hypogonadism (2018) · Human randomized comparative trial Testosterone increased in all three groups, without a significant between-group difference. The combined group had a greater reported improvement in symptom scores. Limitation: Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims. Studied: Men with hypogonadism who wished to preserve fertility. | FDA-approved | FDA label |
| Leuprolide | Historical prostate-cancer comparison (1984) · Human randomized trial Hormonal suppression and overall response were similar; adverse-effect patterns differed. One-year survival was not significantly different. Limitation: This is historical evidence against an older comparator, not a ranking of today’s treatment options. Prostate-cancer findings do not establish benefit for every other leuprolide indication. Studied: 199 patients with previously untreated metastatic prostate cancer. | FDA-approved | FDA label |
| Oxytocin | Route comparison after vaginal birth (2018) · Human randomized trial The primary bleeding endpoint was not significantly different. Severe postpartum bleeding, a secondary endpoint, occurred in 4.6% versus 8.1%, favoring intravenous administration. Limitation: Both groups received oxytocin under clinical supervision. This addresses route selection after delivery, not bonding, mood, or unsupervised nasal-spray use. Studied: 1,075 women randomized; 1,035 included in analyses at an Irish maternity unit. | FDA-approved | FDA label |
| Triptorelin | Combined TEXT / SOFT analysis (2014) · Human randomized combination-treatment trials Five-year disease-free survival was 91.1% versus 87.3%: hazard ratio 0.72. Overall survival was not significantly different. Limitation: The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone. Studied: 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis. | FDA-approved | FDA label |
| Randomized human trials (1)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. | |||
| Melanotan II | Melanotan II · organic erectile dysfunction (2000) · Human randomized trial Erections followed 12 of 19 Melanotan II injections compared with 1 of 21 placebo injections. Severe nausea followed 4 of 19 Melanotan II injections. Limitation: Very small and short. Side effects were common, and the drug was not approved. Studied: 10 men with organic erectile dysfunction. | Not approved | Trials only |
| Small or uncontrolled human studies (3)Human reports without randomization, such as pilots, case series or open-label studies. | |||
| Gonadorelin | Multicenter pulsatile GnRH clinical series (1990) · Human clinical series Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%. Limitation: These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context. Studied: 109 women with primary or secondary hypothalamic amenorrhea. | Withdrawn | Very limited |
| Kisspeptin-10 | LH secretion experiment (2011) · Small human physiology study LH increased, and infusion changed LH pulse frequency and size. Testosterone also increased in the prolonged-infusion experiment. Limitation: These are reproductive-hormone endpoints, not pregnancy, live-birth, or sexual-function outcomes. Findings for kisspeptin-10 should not be conflated with trials of kisspeptin-54. Studied: Healthy men in small bolus and infusion experiments. | Not approved | Very limited |
| Kisspeptin-54 | Kisspeptin-54 triggering of egg maturation (2014) · Human dose-ranging study Egg maturation was observed, and fertilization with embryo transfer occurred in 49 of 53 participants. The study reported 12 clinical pregnancies. Limitation: This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage. Studied: 53 women undergoing IVF. | Not approved | Very limited |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.
Bremelanotide is a prescription melanocortin agonist studied for a defined form of low sexual desire associated with distress. It is also known as PT-141.
Prescription medicines
Read the studies →Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.
Prescription medicines
Read the studies →Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.
Research topics
Read the studies →Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.
Research topics
Read the studies →Kisspeptin-10 is a short active kisspeptin sequence studied in reproductive-hormone regulation. Hormonal responses are a starting point for fertility research.
Research topics
Read the studies →Kisspeptin-54 is a reproductive-signaling peptide studied as an egg-maturation trigger during IVF. It is a distinct form from the shorter kisspeptin-10 already covered in this directory.
Research topics
Read the studies →Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Prescription medicines
Read the studies →Melanotan II is a synthetic, ring-shaped analog of alpha-MSH that darkens skin by acting on melanocortin receptors throughout the body. About 23 people were given it in small studies from 1996 to 2000; it was never approved, and case reports link it to changing moles, melanoma and other serious harms. It is a different drug from the approved afamelanotide (Scenesse) and bremelanotide (Vyleesi).
Research topics
Read the studies →Oxytocin is a peptide hormone used in supervised obstetric care. Its established clinical context should be separated from popular social or wellness claims.
Prescription medicines
Read the studies →Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Prescription medicines
Read the studies →See something wrong on this page? Report a mistake · Corrections